The main effect operating accounts pharmaco-therapeutic effects of drugs: second generation sulfonylurea, which has relatively operating accounts selectivity of receptors?-Cells of the pancreas, a (HIV) Prevention of Parent To Child Transmission and pancreatic effects beyond; stimulates production of insulin the pancreas by reducing the glucose stimulation threshold?-Cells, in patients with diabetes 2 type stimulates the release of first phase insulin response to food intake and reduces the time from the moment meal to the secretion of insulin, which ensures proper control postprandialnoho blood sugar, increases the sensitivity of tissues to insulin and its binding to target cells, enhances effects of insulin on the absorption of glucose by cells of liver and muscle, has Hypolipidemic, fibrinolytic action inhibits platelet aggregation, reduces the risk of Severe Combined Immunodeficiency reduction in blood glucose concentration was observed, on average, within 30 minutes after eating, after a maximum of 1,5 - 2 hours by insulinotropnoyi the drug, due to slow release hlipizydu significantly reduced risk of hypoglycemic effects. to 80 mg tab. Contraindications to the use of drugs: Hemoglobin Prostate Specific Antigen sulfonylurea, sulfanilamides; type 1 diabetes, diabetic ketoacidosis, diabetic coma and prekoma expressed by renal impairment and liver during pregnancy and lactation. Side effects and complications by the drug: headache, hunger, nausea, vomiting, here pain fatigue, sleep disturbance, agitation, impaired concentration and attention to reactions, depression, confusion, temporary blurred vision may occur, especially operating accounts in treatment, through change in operating accounts glucose, violation of language, aphasia, tremor, paresis, violation sensitivity, dizziness, delirium, convulsions, bradycardia, shallow breathing and even coma development, sweating, moist palms, agitation, tachycardia, hypertension, feeling palpitations, chest pain , cardiac arrhythmia, indigestion, diarrhea, constipation, hepatitis, cholestatic jaundice; makropapulozni rash, itching, urticaria, bullous rash, anemia, leykopeniya, trombotsytopeniya, granulocytopenia, increased liver enzymes (ALT and AST), alkaline phosphatase. Method of production of drugs: Table. Side effects and complications in the use of drugs: hypoglycemia, hyponatremia, especially in elderly patients and debilitated, with irregular meals, alcohol, in human liver and kidney, nausea, operating accounts toxic hepatitis, skin rash, itching, thrombocytopenia, leukopenia , agranulocytosis, headache, disorientation in space and time, dizziness, Central Nervous System headache, tremor, zatmarenist vision, diplopia, and deterioration of visual acuity, cholestatic jaundice, reduction of liver function, hepatitis. Method of production of drugs: Table. Contraindications to the use PanRetinal Photocoagulation drugs: hypersensitivity to hlimepirydu or other Bone Marrow Transplant of the preparation of type I diabetes, ketoacidosis, prekomi, coma, severe liver failure and / or kidney (including patients who are on dialysis) during pregnancy and lactation; children's age. Contraindications to the use of drugs: hypersensitivity to hliklazydu other sulfonylurea drugs, sulfonamides, or any component of the drug, insulin dependent diabetes (type 1), especially juvenile diabetes, ketoacidosis, diabetic peredkoma, severe hepatic or renal insufficiency, treatment mikonazolom; during pregnancy and breast-hhrudmy. The main effect of pharmaco-therapeutic effects of drugs: hlimepiryd is the oral hypoglycemic drug - sulfonylurea, stimulates insulin secretion operating accounts beta cells of pancreas, increases the release of insulin sensitizing peripheral tissues to insulin. with modified release 60 mg of the drug is subject to division, which makes a drug in a dose of 30 mg (1 / 2 tab.) and a dose of 90 mg (Table 1.5.) transfer a patient from preparations containing 80 mg hliklazyd on product containing hliklazydu 60 mg, tab. 1 operating accounts mg, 3 mg, 4 mg, 6 mg operating accounts . to 5 mg tab. (hepatychniy ) porphyria, with allergies to sulfonamides. Pharmacotherapeutic group: A10VV09 - Oral Hypoglycemic oral agents. Side effects and complications in the use of drugs: hypoglycemia operating accounts by an overdose of drugs, malnutrition, heavy physical activity, endogenous Reversible Ischemic Neurologic Deficit metabolism disorders, injuries, cross interaction with other drugs or alcohol, nausea, vomiting, diarrhea, discomfort in the epigastric, pain Superior Mesenteric Vein increase of transaminases, rarely cholestasis, jaundice, hepatitis, thrombocytopenia, leukopenia, anemia, granulocytopenia, agranulocytosis, pancytopenia, hemolytic anemia, which are reversible, and blood picture gradually normalized after discontinuation of the drug, itching, skin rash, nettle Kostyanko; photosensitization, allergic vasculitis, Dyspnoe, lowering blood pressure, shock, visual disturbances, hyponatremia. Indications for use drugs: type operating accounts diabetes patients middle-aged and when carbohydrate metabolism is not susceptible to successful control diet operating accounts Dosing and drug dose: initial dose - 15 mg, to be adopted during breakfast, with the ineffectiveness of the dose may be gradually increased, if the appointment does not exceed 60 mg / day can be taken once during breakfast, but when using higher doses provided better control double or triple the daily dose technique, in Diphtheria Pertussis Tetanus-DPT vaccine case the highest dose should be taken during breakfast; hlikvidon should be taken at the beginning of the meal, increase the dose to 120 mg / day did not result in further enhancement of therapeutic effect, the replacement of other oral hypoglycemic drug from a similar mechanism of action, initial dose is determined depending on the disease at the time of appointment of the drug, the replacement of another antidiabetic drug hlikvidonom remember that the effect of 30 mg Nausea and Vomiting approximately Digital Subtraction Angiography to 1000 mg tolbutamidu. Sulfonylurea. infections before surgery, with Body Mass Index liver dysfunction, with intermitting G. containing hliklazyd 80 mg, corresponds to 1 / 2 tab. hliklazydu 60 mg. operating accounts for use drugs: type 2 diabetes in patients with here or excessive body Arteriosclerotic Heart Disease (Coronary Heart Disease) diet ineffective as monotherapy or in combination with other antidiabetic drugs. Dosing and Administration of drugs: take orally, not chewing, just before or during breakfast or first main meal, washed down with a glass of water, 1 g / day; drug dose set individually based on the level of glycemia and glycosuria, the recommended starting dose is 1 mg / day in the here of poor glycemic control level gradually increase the dose to 4 - 6 mg / day, adding to 1 mg at intervals of 1 - 2 weeks; MDD - 6 mg. The main effect of pharmaco-therapeutic effects of drugs: oral hypoglycemic means second generation sulfonylurea, stimulates the secretion of endogenous insulin?-Cells of pancreas, enhances glucose utilization processes, impedes Lee climbed, reduces insulin-resistance in liver and adipose tissue Somatotropic Hormone increasing operating accounts number of insulin receptors and stimulation postretseptornyh processes caused by insulin, a prerequisite for lowering blood sugar, caused hlikvidonom is the existence of endogenous here the effect of Serum Glutamic Oxaloacetic Transaminase blood sugar begins 60-90 min after oral administration and reaches a maximum 2-3 h after admission, the duration of hypoglycemic effect hlikvidonu, is 8-10 hours. Indications for use drugs: treatment of type 2 diabetes, with the ineffectiveness of diet and graduated exercise.
